This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Theravance Biopharma, Inc.
Drug Names(s): TD-6424, Arbelic
Description: Telavancin (TD-6424) is an injectable antibiotic with multiple mechanisms of action. It is a novel lipoglycopeptide that produces a rapid and concentration-dependent killing of clinically relevant gram-positive organisms in vitro. Telavancin inhibits the formation of the bacterial cell wall and disrupts bacterial cell membrane integrity.
Astellas Pharma no longer reports revenues for Vibativ as of Q1 2012. Because of this, BMT is no longer forecasting revenues for this drug.
Theravance and Astellas
In December 2005, Theravance and Astellas Pharma finalized a partnership agreement for the development and marketing of telavancin. Theravance will lead the development of telavancin for cSSSI and HAP and collaborate substantially with Astellas in marketing in the US for the first three years. Astellas will lead all other development, regulatory, manufacturing, sales and marketing activities worldwide, except Japan. Theravance will be responsible for substantially all costs to develop telavancin for cSSSI and HAP and Astellas will be responsible for substantially all costs associated with commercialization and further development of telavancin. Japan is excluded from the agreement.
Aside from various milestone payments, Theravance will receive royalties on aggregate, annual global sales of...See full deal structure in Biomedtracker
Partners: Astellas Pharma, Inc. Clinigen Group plc R-Pharm Group SciClone Pharmaceuticals, Inc. Pharmascience Inc.
Pink Sheet Vibativ Clinical Development
Additional information available to subscribers only: